CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients

International Journal of Hematology
Yunfei ShiXianghong Li

Abstract

To investigate the prognostic value of tumor-infiltrating T-cell density and programmed cell death ligand-1 (PD-L1) expression in diffuse large B cell lymphoma (DLBCL). One-hundred-twenty-five Chinese DLBCL patients were enrolled in our study and provided samples; 76 of all cases were treated with rituximab (R). Tumor tissues were immunostained and analyzed for CD3+ and CD8+ tumor-infiltrating T-cell density, tumoral PD-L1, and microenvironmental PD-L1 (mPD-L1). The density of CD3 was rated as high in 33.6% cases, while 64.0% of DLBCLs were classified as high CD8 density. Of all cases, 16.8% were PD-L1+. Of the remaining PD-L1-DLBCLs, 29.8% positively expressed mPD-L1. Both CD3 high density and CD8 high density were associated with mPD-L1 positivity (P = 0.001 and P = 0.0001). In multivariate analysis, independently, high CD3 density predicted better OS (P = 0.023), while CD8 high density and PD-L1 positivity were both associated with prolonged PFS (P = 0.013 and P = 0.036, respectively). Even in the subgroup treated with R, univariate analyses indicated that high CD3 density and PD-L1 positivity were associated with better OS (P = 0.041) and PFS (P = 0.033), respectively. The infiltrating densities of CD3+ T-cells, CD8+ T-cell...Continue Reading

References

Aug 24, 2006·Expert Review of Anticancer Therapy·Gerhard HeldMichael Pfreundschuh
Dec 23, 2009·International Journal of Cancer. Journal International Du Cancer·Ioanna E GalaniAdelheid Cerwenka
Dec 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul N MeyerDennis D Weisenburger
Apr 28, 2011·Cancer·Jules GadiotChristian Blank
Mar 16, 2012·Nature Reviews. Cancer·Wolf Herman FridmanJérôme Galon
Jun 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tina Marie GreenMichael Boe Møller
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathalie A JohnsonRandy D Gascoyne
Jan 22, 2013·Blood·Heike HornUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group
Nov 13, 2013·Laboratory Investigation; a Journal of Technical Methods and Pathology·Vamsidhar VelchetiDavid L Rimm
Dec 7, 2013·Virchows Archiv : an International Journal of Pathology·Hajnalka RajnaiÁgota Szepesi
Jul 11, 2014·Nature Reviews. Cancer·David W Scott, Randy D Gascoyne
Nov 11, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hidenobu IshiiTomoaki Hoshino
Feb 16, 2015·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A WangG T Liu
Nov 7, 2015·Blood·Vassiliki A Boussiotis
Mar 13, 2016·Cancer Immunology Research·Andrew GabrielsonAiwu Ruth He
Aug 20, 2016·JAMA Oncology·Patricia GauleDavid L Rimm
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr

❮ Previous
Next ❯

Citations

Mar 26, 2019·Cytopathology : Official Journal of the British Society for Clinical Cytology·Katsumi KobataMorishige Takeshita

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.